665 related articles for article (PubMed ID: 10385214)
21. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.
Fang J; Bourin M; Baker GB
Naunyn Schmiedebergs Arch Pharmacol; 1999 Feb; 359(2):147-51. PubMed ID: 10048600
[TBL] [Abstract][Full Text] [Related]
22. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
24. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
25. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
26. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
Nakashima A; Kawashita H; Masuda N; Saxer C; Niina M; Nagae Y; Iwasaki K
Xenobiotica; 2005 Jun; 35(6):589-602. PubMed ID: 16192110
[TBL] [Abstract][Full Text] [Related]
27. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
28. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
29. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.
Olesen OV; Linnet K
Br J Clin Pharmacol; 2000 Dec; 50(6):563-71. PubMed ID: 11136295
[TBL] [Abstract][Full Text] [Related]
30. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Nakajima M; Nakamura S; Tokudome S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Dec; 27(12):1381-91. PubMed ID: 10570018
[TBL] [Abstract][Full Text] [Related]
31. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
VandenBranden M; Ring BJ; Binkley SN; Wrighton SA
Pharmacogenetics; 1996 Feb; 6(1):81-91. PubMed ID: 8845864
[TBL] [Abstract][Full Text] [Related]
32. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes.
Patten CJ; Smith TJ; Friesen MJ; Tynes RE; Yang CS; Murphy SE
Carcinogenesis; 1997 Aug; 18(8):1623-30. PubMed ID: 9276639
[TBL] [Abstract][Full Text] [Related]
33. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
Ono S; Hatanaka T; Miyazawa S; Tsutsui M; Aoyama T; Gonzalez FJ; Satoh T
Xenobiotica; 1996 Nov; 26(11):1155-66. PubMed ID: 8948091
[TBL] [Abstract][Full Text] [Related]
34. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
36. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
37. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
[TBL] [Abstract][Full Text] [Related]
38. In vitro effects of tacrolimus on human cytochrome P450.
Lecointre K; Furlan V; Taburet AM
Fundam Clin Pharmacol; 2002 Dec; 16(6):455-60. PubMed ID: 12685503
[TBL] [Abstract][Full Text] [Related]
39. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes.
Kerlan V; Dreano Y; Bercovici JP; Beaune PH; Floch HH; Berthou F
Biochem Pharmacol; 1992 Nov; 44(9):1745-56. PubMed ID: 1449532
[TBL] [Abstract][Full Text] [Related]
40. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
